Welcome to today’s Biotech Spotlight, a series featuring companies creating breakthrough technologies and products. Today, we’re looking at Fractyl Health, a company that recently announced a significant pivot that could allow it to cash in on the GLP-1 boom — and beyond.
In focus with: Dr. Harith Rajagopalan, CEO and co-founder, Fractyl Health
Dr. Harith Rajagopalan, CEO, co-founder, Fractyl Health
Permission granted by Fractyl Health
The company’s vision: Fractyl Health is working to solve an issue emerging alongside the rising use of GLP-1 drugs for obesity: What happens to patients whose weight returns after they stop using the medications.
For Fractyl the answer could be an endoscopic procedure called Revita. The approach, which won breakthrough designation status from the FDA for patients who have…